Keeping You Informed

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.

Given the rising incidence of colorectal cancer — particularly among younger adults — and ongoing threats to preventive screening in the U.S., the need for timely, optimized CRC screening is greater than ever.

The 340B Drug Pricing Program was created to improve access to care for low-income and uninsured patients at safety-net hospitals and clinics.

Some cancers are sadly more deadly and more brutal than others – pancreatic cancer being one of them.

Advocacy Chat – Up Next: Dare to Imagine A World .....

Advocacy Chat, CPAN Chapter Spotlight, Cancer News You Can Use .....

Advances in medicine, technology, and knowledge have increased patients’ chances .....